Clinical update of medications associated with QT prolongation among COVID-19 patients
E Herbert, D Fournier - The European Research Journal, 2022 - dergipark.org.tr
In the struggle against COVID-19 pandemic, chloroquine (CQ)(a 4-aminoquinoline) and its
derivative hydroxychloroquine (HCQ) have both been used as a potential form of treatment …
derivative hydroxychloroquine (HCQ) have both been used as a potential form of treatment …
Terapias biológicas ea pandemia do século XXI
JFA Azougado - 2022 - repositorio.ul.pt
Ao longo da história da humanidade diferentes episódios pandémicos tornaram-se episódio
nefastos que levaram a uma mudança de paradigma das sociedades. Tiveram por base a …
nefastos que levaram a uma mudança de paradigma das sociedades. Tiveram por base a …
Mise au point d'un nouveau test antiviral in vitro contre le coronavirus HCoV-OC43 et évaluation de l'huile essentielle des bourgeons de P. balsamifera
L Girard - 2024 - constellation.uqac.ca
La capacité limitée de la prise en charge des maladies virales infectieuses incite de plus en
plus la communauté scientifique à se pencher davantage vers les produits d'origine …
plus la communauté scientifique à se pencher davantage vers les produits d'origine …
[HTML][HTML] Chez les adultes atteints de la COVID-19 d'intensité légère à modérée, non vaccinés et à risque de complications, est-ce que le nirmatrelvir/ritonavir diminue …
L Lanthier, MÉ Plourde, M Cauchon - La Revue de Médecine …, 2022 - ncbi.nlm.nih.gov
Chez les adultes atteints de la COVID-19 d’intensité légère à modérée, non vaccinés et à
risque de complications, est-ce que le nirmatrelvir/ritonavir diminue le risque d’hospitalisation …
risque de complications, est-ce que le nirmatrelvir/ritonavir diminue le risque d’hospitalisation …
Infectious comorbidities in severity and mortality from COVID-19: analysis of the scientific contribution in the lancet publishing group.
JC Sandoval Trigos, MR Vásquez Ramírez… - 2022 - cabidigitallibrary.org
The number of total cases of coronavirus disease-2019 (COVID-19) continues to rise rapidly,
threatening thousands or millions of people with pre-existing chronic conditions who are …
threatening thousands or millions of people with pre-existing chronic conditions who are …
In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease …
L Lanthier, ME Plourde, M Cauchon - La Revue de Medecine …, 2022 - europepmc.org
[In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at
risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related …
risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related …
COVID-19 の経口治療薬開発に向けたハイブリッド型in Silico 創薬
小清水初花， 小野純一， 福西快文… - Journal of Computer …, 2022 - jstage.jst.go.jp
抄録 Hybrid in silico drug discovery was performed by combining large-scale quantum
molecular dynamics (QMD) simulations with the conventional in silico drug discovery …
molecular dynamics (QMD) simulations with the conventional in silico drug discovery …